SGRL · Shree Ganesh Remedies Ltd · Biotechnology & Drugs
SGRL · Shree Ganesh Remedies Ltd · Biotechnology & Drugs
As of 06 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹14 Cr
Revenue YoY
PAT YoY
-67.5%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
5.4
P/S (TTM)
6.3
Sector P/E
33.6
Dividend yield
0.0%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| SGRL (this stock) | 53.2 | 5.4 | +15.6% | +9.5% | 0.19 | 0.0% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 78.2 | 20.7 | +13.7% | Not available from data source | 141.16 | +0.7% |
| Cipla | 35.1 | 4 | +11.9% | +9.8% | 0.02 | +0.9% |
Promoter
stable
FII
stable
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in SGRL's filed documents yet.